Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
Copyright © 2019 Shiori Ando, Arisu Sato, Michinori Funato, Kazuki Ohuchi, Satoshi Inagaki, Shinsuke Nakamura, Masamitsu Shimazawa, Hideo Kaneko, Hideaki Hideaki Hara et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Ando, S. , Sato, A. , Funato, M. , Ohuchi, K. , Inagaki, S. , Nakamura, S. , Shimazawa, M. , Kaneko, H. and Hideaki Hara, H. (2019) The Effects of Rufinamide on
in Vitro Spinal Muscular Atrophy Model.
Pharmacology & Pharmacy,
10, 159-168. doi:
10.4236/pp.2019.104014.